Non-motor symptoms in a PPMI cohort of p.A53T α-synuclein mutation-related and sporadic Parkinson’s disease patients
Objective: To evaluate the prevalence of non-motor symptoms in p.A53T α-synuclein (SNCA) related Parkinson's disease (PD) as compared to sporadic Parkinson's disease (sPD) patients. Background:…Validation study of Parkinson anxiety scale, Czech version
Objective: The study aims to evaluate psychometric properties of Czech version of Parkinson Anxiety Scale (PAS), new scale developed in 2014 to measure anxiety specifically…Constipation in early de novo Parkinson’s disease: Prevalence and correlates with clinical features, imaging and non-imaging biomarkers
Objective: To explore the association between constipation and clinical features, imaging and non-imaging biomarkers in early de novo (untreated) Parkinson's disease (PD) patients. Background: Constipation…Reliability of a newly developed protocol for fiberoptic endoscopic evaluation of swallowing in Parkinson’s patients (PARK-FEES)
Objective: A new FEES protocol specified for dysphagia diagnosis among Parkinson's disease (PD) patients was recently developed in a prior two-phased study¹, which is now…Clinical efficacy of istradefylline on lower urinary tract symptoms in Parkinson’s disease: A prospective study
Objective: The aim of the present study was to determine the effects of istradefylline, adenosine A2A receptor antagonist on lower urinary tract symptoms (LUTS) in…Exploring association of GBA variants with pre-diagnostic features of PD in the PREDICT-PD cohort: A nested case-control study
Objective: To investigate the association of GBA variants with pre-diagnostic features of Parkinson's disease (PD) within the PREDICT-PD cohort. Background: Subtle motor and non-motor symptoms…α-synuclein CSF levels correlate with urinary dysfunction in early de novo Parkinson’s disease patients
Objective: To explore the association between levels of α-synuclein burden and urinary dysfunction in early de novo (untreated) Parkinson's disease (PD) patients. Background: Urinary dysfunction…The dopamine agonist withdrawal syndrome rating scale (DAWS-RS): Initial development of a new non-motor scale
Objective: To describe the development of the dopamine agonist withdrawal syndrome (DAWS) rating scale (DAWS-RS), a new questionnaire designed to evaluate the symptoms, severity, and…Is continuous twenty four hour blood pressure monitoring a suitable tool in evaluating sleep disturbances in Parkinson’s disease?
Objective: To compare blood pressure (BP) changes in nighttime by continuous twenty four hour blood pressure monitoring (RR) as a postulated tool to describe sleep…Identification of barriers preventing disclosure of non-motor symptoms in Parkinson’s patients to healthcare providers
Objective: 1) To identify patient barriers to help-seeking for non-motor symptoms (NMS) from their Parkinson's healthcare provider, 2) To determine whether barriers are symptom specific…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.